To explore the contributions of CD4 and CD8 TILs to anti-tumor efficacy, heterologous PROSTVAC-V/F immunotherapy was performed in mice that were selectively depleted of CD8 T cells (Figure 5A) or CD4 T cells (Figure 5D). The gene discussed is CD4; the disease is neoplasm.